Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

YiChang HEC ChangJiang Pharmaceutical Co Ltd

YiChang HEC ChangJiang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)9.02
  • Today's Change0.20 / 2.27%
  • Shares traded776.20k
  • 1 Year change+8.81%
  • Beta0.8947
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.

  • Revenue in HKD (TTM)6.05bn
  • Net income in HKD1.80bn
  • Incorporated2001
  • Employees4.89k
  • Location
    YiChang HEC ChangJiang Pharmaceutical Co LtdZhen An Road No. 368Shangsha Village, Chang'an TownDONGGUAN 443300ChinaCHN
  • Phone+86 76 981768866
  • Fax+86 76 981768866
  • Websitehttp://www.hec-changjiang.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
1558:HKG since
announced
Transaction
value
Dongguan Hec Taigen Biopharmaceuticals Co LtdAnnounced22 Nov 202322 Nov 2023Announced7.13%4.98m
Data delayed at least 15 minutes, as of Nov 01 2024 08:08 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ocumension Therapeutics338.94m-352.52m4.58bn477.00--1.28--13.53-0.5379-0.53790.5174.360.1032.402.48763,383.40-10.71-38.78-11.55-41.4758.2962.30-104.01-975.825.00--0.0055--54.99--5.68--319.66--
Beijing Luzhu Biotechnology Co Ltd0.00-305.78m4.87bn148.00--4.76-----1.51-1.510.005.090.00----0.00-23.80---25.44----------5.91--0.0296------65.62------
Shandong Boan Biotechnology Co Ltd786.30m67.51m4.88bn777.0068.723.0534.086.210.13260.13261.542.990.30691.102.60967,157.302.63--3.43--74.10--8.59--1.034.010.3369--19.80--64.02------
Tong Ren Tang Technologies Co Ltd7.51bn710.87m6.54bn4.01k9.210.84444.600.87120.5550.5555.876.050.50260.98815.221,831,768.007.427.6811.6912.3240.9743.5014.7616.112.30--0.196839.9413.046.011.25-2.73-22.26-0.0089
Sihuan Pharmaceutical Holdings Group Ltd1.92bn-41.29m6.80bn2.65k--1.41--3.55-0.0045-0.00450.20650.51820.15060.8943.90667,311.90-1.77-6.85-2.68-9.1065.9175.81-11.78-36.231.50--0.181---14.70-8.6097.23--0.9325--
Beijing Tong Ren Tang Chinese Medicine1.38bn494.14m6.81bn779.0013.771.7911.014.940.59030.59031.644.550.32840.35543.621,725,133.0012.7216.7114.0918.7572.0669.8838.7240.729.55--0.032768.87-11.910.1459-16.33-1.43-16.307.49
Consun Pharmaceutical Group Ltd2.99bn913.63m6.99bn3.18k7.301.736.992.341.131.133.714.790.52092.0012.89956,784.4015.9712.0423.2419.2574.2274.5530.6624.892.80--0.114440.8410.717.0314.8811.01-22.9318.43
China Shineway Pharmaceutical Group Ltd4.59bn1.21bn7.61bn3.23k5.760.94945.461.661.601.606.089.690.44761.285.261,336,654.0011.768.0315.479.7775.2174.5526.2717.873.14--0.045736.2914.3211.9434.1413.890.639612.88
Yichang Hec Changjiang Pharmactcl Co Ltd6.05bn1.80bn7.76bn4.89k4.310.823.711.282.052.056.8810.760.42722.503.741,310,494.0011.698.0317.2711.8178.9079.9727.3720.801.9350.790.212615.8168.0820.182,501.2416.15-11.50--
AIM Vaccine Co Ltd1.29bn-1.30bn9.10bn1.56k--2.38--7.03-1.07-1.071.073.160.14620.63251.10796,494.10-22.69---37.16--72.34---155.22--0.6836-6.610.3437---6.06---307.07------
Everest Medicines Ltd457.20m-1.15bn10.25bn520.00--2.10--22.42-3.57-3.571.4215.020.07565.233.221,058,327.00-19.03-30.52-20.21-33.1475.74---251.64-5,745.254.62--0.1119--884.46---241.50--4.65--
Luye Pharma Group Ltd6.90bn841.60m10.50bn5.23k12.470.7386.201.520.22370.22371.833.780.2362.443.021,308,626.003.112.805.474.4568.7370.5313.1810.391.203.140.410311.822.703.50-11.94-16.39-14.05--
SSY Group Ltd6.47bn1.37bn11.15bn5.80k8.211.546.101.720.45930.45932.182.440.54182.753.071,155,141.0011.5410.5114.8814.0354.3958.7221.3018.622.0628.650.32338.560.45059.1017.447.663.9413.56
Data as of Nov 01 2024. Currency figures normalised to YiChang HEC ChangJiang Pharmaceutical Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

5.33%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 02 Oct 202415.10m2.31%
Dimensional Fund Advisors LPas of 03 Oct 20246.53m1.00%
GF Fund Management Co., Ltd.as of 30 Jun 20243.89m0.60%
Norges Bank Investment Managementas of 30 Jun 20242.98m0.46%
BlackRock Fund Advisorsas of 03 Oct 20242.76m0.42%
BlackRock Advisors (UK) Ltd.as of 03 Oct 20241.01m0.16%
American Century Investment Management, Inc.as of 03 Oct 2024951.00k0.15%
State Board of Administration of Florida Retirement Systemas of 30 Jun 2024642.40k0.10%
China Asset Management (Hong Kong) Ltd.as of 30 Sep 2024498.00k0.08%
SSgA Funds Management, Inc.as of 03 Oct 2024490.60k0.08%
More ▼
Data from 30 Jun 2024 - 22 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.